GSK/Desano Tie-Up To Bring Large Dolutegravir Price Cuts
This article was originally published in PharmAsia News
Executive Summary
HIV drug Tivicay is expected to become cheaper in China under a recent manufacturing deal between ViiV and Desano. The Chinese firm expects to gain a 35% share of the global generic antiretroviral API supply market this year after patent licensing agreements with the Medicines Patent Pool.